Towards the Next 45 Years: Driving Growth and Transformation with Insight
For more than 45 years, Michael Allen Company (MAC) has focused on serving the life sciences and pharmaceutical sectors, providing insight-centric market and strategic consulting. We help clients make faster, more accurate decisions in complex environments to achieve sustainable growth and a competitive edge.
I. Steady Progress: 45 Years of Continuous Growth and Trust
To this day, we have built our foundations on professionalism, integrity, and deep industry insight, providing strategic services to the world’s leading pharmaceutical and life sciences companies. We have accompanied clients in achieving business breakthroughs and value enhancement across numerous countries and therapeutic areas. These long-term partnerships and repeat engagements not only validate our professional capabilities but also solidify the strong trust between us and our industry partners.
II. Technology-Enabled: The Insight-Driven Decision Platform
In an era of information overload, precise and actionable data insight is the key to success. We not only provide strategic consulting but also convert complex data into clear business conclusions and actionable recommendations through our proprietary methods and tools.
WayFinder℠: Precision Navigation for Transaction and Partnership Decisions
WayFinder℠ offers a one-stop solution for asset evaluation and decision support in scenarios like in-licensing, out-licensing, M&A, and partnerships. Built on high-quality healthcare data (such as claims and medical records), it integrates insights from Key Opinion Leaders (KOLs) interviews, prescribing behaviors, and patient/payer perspectives. It consolidates key elements like competitive intelligence, market forecasting, commercial value assessment, and pipeline analysis into a single, streamlined delivery. WayFinder℠ can also be extended to investment due diligence, valuation, and market access strategies (pricing, reimbursement and payer dynamics, and market tracking). This integrated approach avoids the time loss, repetitive communication, and inconsistencies of using multiple vendors, ensuring synergy and implementation efficiency. Backed by deep disease-area knowledge, real-world industry experience, and proven methodologies, WayFinder℠ consistently delivers high-quality, actionable insights to help you make smarter choices, faster.
ViewFinder™: Building a Data-to-Decision Loop
ViewFinder™ deeply profiles market size, patient journeys, demand forecasts, and segmentation trends. It is not just a “reporting tool” but an end-to-end decision support system for brand teams, helping them identify opportunities, formulate forward-thinking strategies, optimize resource allocation, and measure impact
SAPPHIRE™: Real-Time Market Insights
The SAPPHIRE™ series continuously tracks high-growth therapeutic areas like oncology. Through modular updates on market dynamics and treatment progress, it provides you with near-real-time trend signals, ensuring you always stay one step ahead in a rapidly evolving landscape.
III. People-Centric: A Culture of Collaboration and Professionalism
We firmly believe that top-tier consulting comes from top-tier talent and highly effective collaboration. Every member of MAC is a key driver of project success.
“What fascinates me is the diversity of projects and therapeutic areas—transforming data into actionable insights is both challenging and incredibly rewarding.”
We foster a culture of open sharing and close collaboration, encouraging mutual trust and collective growth. This culture not only sparks continuous innovation but also ensures we deliver consistent, actionable strategic solutions to our clients.
IV. Proven by Data: An Exceptional Team and Results
Excellence is more than a slogan; it’s reflected in quantifiable results. The following data is a direct testament to Michael Allen Company’s professional strength and client trust.
100%
of consulting staff hold degrees from Ivy League schools
100%
of projects are managed by Senior Leadership
22
average years of biopharma experience at the executive level
100%
of consulting staff hold advanced degrees (MA+)
90%
of our business comes from existing clients
0%
reliance on off-shore resources
Source: Michael Allen Company internal statistics; for demonstrating team and operational characteristics.
V. Our Core Strengths
Proven Record of Excellence
For more than 45 years, we've been a trusted advisor to the world's leading companies, delivering results through top talent, client trust, and industry expertise.
Focus on Biopharma
We serve the life sciences and pharmaceutical industry, focusing specifically on sales and marketing, and driving success through decades of excellence.
Innovative Research Technology
We advance research and data collection technology for high-quality analyses, transforming insights with innovative solutions and global expertise.
High Touch, with Global Reach
Our projects span 40+ countries, are always managed by an Executive, and staffed with seasoned in-house consulting staff (no off-shoring).
Extensive Therapeutic Area
With expertise in 100+ therapeutic areas, our comprehensive solutions address over 100 conditions with significant focus on oncology and orphan diseases.
Experts in Analytics and Integration
We have worked with 85% of the Top 20 Global Pharma Companies, integrating multiple data sources to develop cutting-edge solutions.
VI. Future Outlook: Your Trusted Strategic Partner for Industry Leadership
Looking ahead, Michael Allen Company will continue to leverage industry-leading methodologies and technological capabilities. By combining AI-driven automated analysis with client-centric strategies, we will work hand-in-hand with all life sciences and pharmaceutical partners in China, driving tangible transformation and growth through insight.
Deep Expertise Coverage
Our experience is both broad and deep, spanning over 100 therapeutic areas. From common diseases to rare disorders, we provide precise strategic guidance backed by profound knowledge.
Oncology (Solid)
- Breast
- CRC
- Esophageal / Gastric / GEJ
- GBM
- HCC
- Melanoma
- NSCLC
- Ovarian
- Pancreatic
- Prostate
- RCC
- SCCHN
- Urothelial
Oncology (Heme)
- AML
- CLL
- DLBCL
- Follicular Lymphoma
- Hodgkin’s Lymphoma
- MDS
- Multiple Myeloma
Rare Diseases
- Acquired Hemophilia
- Cystic Fibrosis
- Factor VII deficiency
- FSHD
- Glanzmann Thrombasthenia
- Growth Hormone Deficiency
- Hemophilia A
- Hemophilia B with Inhibitors
- Hypertrophic Cardio Myopathy
- Interstitial Cystitis
- Lennox-Gastaut Syndrome
- Multiple Sclerosis
- Primary Immunodeficiency
- Progressive Supra-Nuclear
- Palsy
CNS / Neurologic
- Addiction Therapy
- ADHD
- Alzheimer’s Disease
- Anxiety
- Bipolar Disorder
- Diabetic Neuropathy
- Epilepsy
- Fibromyalgia
- Insomnia
- MDD
- Migraine
- Neuropathic Pain
- Opioid Use Disorder
- Parkinson’s Disease
- Schizophrenia
- Smoking Cessation
- Spinal Cord Injury
Immune-mediated
- Actinic Keratosis
- Ankylosing Spondylitis
- Atopic Dermatitis
- Crohn’s Disease
- Gout
- Osteoarthritis
- Psoriatic Arthritis
- Psoriasis
- Rheumatoid Arthritis
- SLE
- Ulcerative Colitis
Cardio-Renal / Metabolic
- Angina
- AHF
- CHF
- CKD
- Hyperlipidemia
- Hypertension
- IHD
- Myocardial Infraction
- NAFLD / NASH
- NVAF
- Obesity
- PAH
- T2DM
- VTE
Virology / Infectious Disease
- HBV
- HCV
- HIV
- Influenza
- Fungal Infections
- COVID-19
Women’s Health
- Adenomyosis
- Contraception
- Endometriosis
- Osteoporosis
- PCOS
- Uterine Fibroids
Other
- Allergy
- Anemia
- Asthma
- BPH
- COPD
- GERD
- IBS
- Macular Degeneration
- Overactive Bladder
- SHPT
Trusted by Industry Leaders
Serving 17 of the world’s 20 largest pharmaceutical companies.
Our Leadership Team
Jean-Olivier Marty, President
22 years of biopharma experience with wide therapeutic area expertise including Immunology, Cardiovascular, Metabolic & Oncology. Areas of focus include SAPPHIRE™ brand health tracker, Market structure / market mapping, Segmentation, Patient flow modeling / forecasting, and Positioning, branding and communication.
Artak Harutunyan, Co-President
24 years of biopharma experience with wide therapeutic area expertise, including Oncology and Rare Diseases. Areas of focus include Market structure / market mapping, Segmentation / positioning / messaging, Patient flow modeling / forecasting, Demand / conjoint studies, and SAPPHIRE™ brand health tracker.
Scott Jamieson, Vice President
34 years of management consulting experience, with 25 years in biopharma and medical products. Strategic and market planning, research and commercial operations expertise.
Grant Tarsi, Vice President
14 years of biopharma experience with broad therapeutic area knowledge. Areas of focus include Real-world data analytics (claims, EHR), Market sizing, Market structure / market mapping, Patient journey / flow modeling, Forecasting, and Demand studies.
Alan Gray, Vice President, Market Access
More than 25 years of Market Access, Asset Commercialization, and Consulting with wide therapeutic area expertise, including Oncology and Rare Diseases. Areas of focus include Market Access for US, EU, Asia; Policy / Value Proposition / Pricing / Payer engagement / Health Economics and Outcome Research; Asset commercialization / Launch planning / Clinical development / Market Research; and US and Global Marketing (oncology).